Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of LGD-6972 Capsule vs Solution
NCT02672839Phase 1Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LGD-6972 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ligand Pharmaceuticals. Primary endpoints: Area Under the Concentration Curve at 14 days and Maximum Concentration at 14 days. Started Feb 2016; status: completed.
02
Drugs
LGD-6972
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02672839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672839.